The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

被引:138
作者
Hartmann, Sylvia [1 ]
Eichenauer, Dennis A. [2 ,3 ]
Pluetschow, Annette [2 ,3 ]
Mottok, Anja [4 ]
Bob, Roshanak [5 ]
Koch, Karoline [6 ,7 ]
Bernd, Heinz-Wolfram [8 ]
Cogliatti, Sergio [9 ]
Hummel, Michael [10 ]
Feller, Alfred C. [8 ]
Ott, German [11 ,12 ]
Moeller, Peter [13 ]
Rosenwald, Andreas [4 ]
Stein, Harald [5 ]
Hansmann, Martin-Leo [1 ]
Engert, Andreas [2 ,3 ]
Klapper, Wolfram [6 ,7 ]
机构
[1] Goethe Univ Frankfurt, Dr Senckenberg Inst Pathol, D-60590 Frankfurt, Germany
[2] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[3] Univ Hosp Cologne, German Hodgkin Study Grp, Cologne, Germany
[4] Univ Wurzburg, Inst Pathol, Wurzburg, Germany
[5] Berlin Reference Ctr Lymphoma & Hematopathol, Pathodiagnost Berlin, Berlin, Germany
[6] Univ Klinikum Schleswig Holstein, Inst Pathol, Haematopathol Sect, Lubeck, Germany
[7] Univ Klinikum Schleswig Holstein, Lymph Node Registry, Lubeck, Germany
[8] Univ Klinikum Schleswig Holstein, Inst Pathol, Lubeck, Germany
[9] Kantonsspital St Gallen, Inst Pathol, St Gallen, Switzerland
[10] Charite, Inst Pathol, Berlin, Germany
[11] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany
[12] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[13] Univ Hosp Ulm, Inst Pathol, Ulm, Germany
关键词
INVOLVED-FIELD RADIOTHERAPY; REED-STERNBERG CELLS; FOLLICULAR LYMPHOMA; GERMINAL-CENTERS; FINAL ANALYSIS; DISEASE; STAGE; RITUXIMAB; PHASE-2; CHEMOTHERAPY;
D O I
10.1182/blood-2013-07-515825
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of all Hodgkin lymphoma cases. The aim of this study was to evaluate the prognostic implication of histopathologic NLPHL variants. Biopsies of 423 NLPHL patients treated within 9 prospective clinical trials performed by the German Hodgkin Study Group were classified as tumor cell-rich cases (n = 10), typical NLPHL (n = 308), or histopathologic variants (n = 105). Histopathologic variants were characterized by the presence of lymphoma cells outside the B-cell nodules or B-cell depletion of the micro-environment. Compared with typical NLPHL, histopathologic variants were associated with advanced disease (29.5% vs 14.6%, P = .0012) and a higher relapse rate (18.1% vs 6.5% at 5 years, P = .0009). Variant histology represented an independent prognostic factor (odds ratio = 2.955) in a multivariate model of progression/relapse. A prognostic score, including the risk factors variant histopathologic growth pattern, low serum albumin, and male gender, was derived from this model and allowed the definition of 3 distinct risk groups. NLPHL patients presenting with histopathologic variants have a poorer outcome compared with those showing typical histology. The newly developed prognostic score combining histologic and clinical features allows allocating NLPHL patients to defined risk groups.
引用
收藏
页码:4246 / 4252
页数:7
相关论文
共 29 条
[1]   Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage [J].
Adam, P ;
Katzenberger, T ;
Eifert, M ;
Ott, MM ;
Rosenwald, A ;
Müller-Hermelink, HK ;
Ott, G .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (12) :1661-1664
[2]  
Borchmann P., 2010, HAEMATOLOGICA S2, V95, pa1146
[3]   Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group [J].
Borchmann, Peter ;
Haverkamp, Heinz ;
Diehl, Volker ;
Cerny, Thomas ;
Markova, Jana ;
Ho, Anthony D. ;
Eich, Hans-Theodor ;
Mueller-Hermelink, Hans Konrad ;
Kanz, Lothar ;
Greil, Richard ;
Rank, Andreas ;
Paulus, Ursula ;
Smardova, Lenka ;
Huber, Christoph ;
Doerken, Bernd ;
Nerl, Christoph ;
Krause, Stefan W. ;
Mueller, Rolf-Peter ;
Fuchs, Michael ;
Engert, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4234-4242
[4]   Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma:: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma [J].
Boudová, L ;
Torlakovic, E ;
Delable, J ;
Reimer, P ;
Pfistner, B ;
Wiedenmann, S ;
Diehl, V ;
Müller-Hermelink, HK ;
Rüdiger, T .
BLOOD, 2003, 102 (10) :3753-3758
[5]   Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease, represent clonal populations of germinal center-derived tumor B cells [J].
Braeuninger, A ;
Kuppers, R ;
Strickler, JG ;
Wacker, HH ;
Rajewsky, K ;
Hansmann, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) :9337-9342
[6]   Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis [J].
Brune, Verena ;
Tiacci, Enrico ;
Pfeil, Ines ;
Doering, Claudia ;
Eckerle, Susan ;
van Noesel, Carel J. M. ;
Klapper, Wolfram ;
Falini, Brunangelo ;
von Heydebreck, Anja ;
Metzler, Dirk ;
Braeuninger, Andreas ;
Hansmann, Martin-Leo ;
Kueppers, Ralf .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (10) :2251-2268
[7]   Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease [J].
Diehl, V ;
Sextro, M ;
Franklin, J ;
Hansmann, ML ;
Harris, N ;
Jaffe, E ;
Poppema, S ;
Harris, M ;
Franssila, K ;
van Krieken, J ;
Marafioti, T ;
Anagnostopoulos, I ;
Stein, H .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :776-783
[8]   Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial [J].
Eich, Hans Theodor ;
Diehl, Volker ;
Goergen, Helen ;
Pabst, Thomas ;
Markova, Jana ;
Debus, Juergen ;
Ho, Anthony ;
Doerken, Bernd ;
Rank, Andreas ;
Grosu, Anca-Ligia ;
Wiegel, Thomas ;
Karstens, Johann Hinrich ;
Greil, Richard ;
Willich, Normann ;
Schmidberger, Heinz ;
Doehner, Hartmut ;
Borchmann, Peter ;
Mueller-Hermelink, Hans-Konrad ;
Mueller, Rolf-Peter ;
Engert, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4199-4206
[9]   Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group [J].
Eichenauer, Dennis A. ;
Fuchs, Michael ;
Pluetschow, Annette ;
Klimm, Beate ;
Halbsguth, Teresa ;
Boell, Boris ;
Von Tresckow, Bastian ;
Nogova, Lucia ;
Borchmann, Peter ;
Engert, Andreas .
BLOOD, 2011, 118 (16) :4363-4365
[10]   Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial [J].
Ekstrand, BC ;
Lucas, JB ;
Horwitz, SM ;
Fan, Z ;
Breslin, S ;
Hoppe, RT ;
Natkunam, Y ;
Bartlett, NL ;
Horning, SJ .
BLOOD, 2003, 101 (11) :4285-4289